I totally agree to the point Vas Narasimhan, CEO of Novartis AG is making in the cited articel. It is not understandable that the public reputation of Pharma industrie is equal to that of the tobaco industry. The way business is done in Pharma (at least in the Association of research-based pharmaceutical industry) has fundamentally changed over the last years. The codex that this industry has given it self and strictly follows, prevents effectively practises that had led to this bad reputation. This article is worth reading.